Cellectis: Monthly Information on Share Capital and Company Voting Rights

(Article 223-16 of General Regulation of the French financial markets authority)

Regulatory News:

Cellectis (Paris:ALCLS):

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of sharesin the capital

 

Total number of votingrights

        
      
      
        
          11/30/2018
        
        
           
        
        
          42,430,026
        
        
           
        
        
          47,447,187
        
      
    
    

About CellectisCellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005433/en/

CellectisMedia:Jennifer Moore917-580-1088VP of [e-mail]

Caitlin Kasunich212-896-1241KCSA Strategic [e-mail]

IR:Simon Harnest646-385-9008VP of Corporate Strategy and [e-mail]